Clicky

Chimerix, Inc.(CMRX)

Description: Chimerix, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of oral antiviral therapeutics for various medical needs. Its lead product includes CMX001, an orally administered drug that has completed Phase II clinical trials for the prevention of cytomegalovirus infection in hematopoietic stem cell transplant recipients; and is in Phase II clinical trials for treating double-stranded DNA viruses comprising herpesviruses, adenoviruses, BK viruses, papillomaviruses, and orthopoxviruses, as well as for the treatment of smallpox. The company also develops CMX157, an oral nucleotide compound that is in Phase I clinical trials to treat HIV infections. It has a collaboration and license agreement with Merck, Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.


Keywords: Medicine Biopharmaceutical Viruses Virus Antiviral Drug Herpes Ebola Hematopoietic Stem Cell Papillomavirus Prodrugs Antivirals Monkeypox Poxviruses Cytomegalovirus Infection Hiv Infections Orthopoxvirus Smallpox Treatment Of Smallpox

Home Page: www.chimerix.com

CMRX Technical Analysis

2505 Meridian Parkway
Durham, NC 27713
United States
Phone: 919 806 1074


Officers

Name Title
Mr. Michael A. Sherman M.B.A. CEO, Pres & Director
Mr. Michael T. Andriole M.B.A. Chief Bus. Officer, Sec. & CFO
Dr. Allen S. Melemed M.B.A., M.D. Chief Medical Officer
Mr. David Jakeman CPA Exec. Director of Fin. & Accounting and Principal Accounting Officer
Dr. Roy W. Ware Chief Manufacturing & Technology Officer
Dr. Randall Lanier Chief Science Officer
Ms. Michelle LaSpaluto VP of Strategic Planning & Investor Relations
Dr. Michael A. Alrutz Sr. VP, Gen. Counsel & Corp. Sec.
Dr. Joshua E. Allen Chief Technology Officer of Imipridones

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 1.2136
Trailing PE: 1.1053
Price-to-Book MRQ: 0.6267
Price-to-Sales TTM: 5.2738
IPO Date: 2013-04-11
Fiscal Year End: December
Full Time Employees: 87
Back to stocks